secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001104659-23-070444
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma prices $4M at-the-market offering, appoints new director, extends loan interest-only period
--------------------------------------------------------------------------------

- Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.
- Abhinav Jain of Nantahala Capital appointed to Board; Board increases from 4 to 5 members.
- Company to focus on Rx segment, de-emphasize or monetize Consumer Health segment, suspend pipeline programs.
- Closing of offering extends interest-only period on $15M Avenue Capital term loan through maturity in January 2025.
- Common warrants (Tranche A & B) exercisable at $1.59/share for up to 4.35M shares; potential additional $7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/0001104659-23-070444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923070444/tm2318372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer